Findings

What do systematic reviews say?

7 questions · 10 findings · 1 reviews · Childhood Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 20%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 20%Moderate 6 · 60%High 0 · 0%

Dexrazoxane vs no cardioprotective intervention or placebo

Heart failure · adults with cancer receiving anthracyclines

Dexrazoxane probably leads to lower clinical heart failure Available case analysis compared with no cardioprotective intervention or placebo (moderate certainty).

1 finding from 1 review

Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes only
RR 0.22 [0.11, 0.43]
7 studies · 1221 participants
Moderate

Dexrazoxane vs no cardioprotective intervention or placebo

Secondary malignant neoplasms · adults with cancer receiving anthracyclines

The review found no eligible studies for this question.

1 finding from 1 review

Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dexrazoxane vs no cardioprotective intervention or placebo

Clinical heart failure and subclinical myocardial dysfunction combined Comparable definitions; see Characteristics of included studies for exact definitions. Available‐case analysis · adults with cancer receiving anthracyclines

Dexrazoxane probably leads to lower clinical heart failure and subclinical myocardial dysfunction… compared with no cardioprotective intervention or placebo (moderate certainty).

2 findings from 1 review

Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes only
RR 0.37 [0.24, 0.56]
3 studies · 417 participants
Moderate
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes only
RR 0.46 [0.33, 0.66]
2 studies · 534 participants
Moderate

Dexrazoxane vs no cardioprotective intervention or placebo

Overall survival (Illustrative comparative risks reported as number of alive participants) · adults with cancer receiving anthracyclines

Dexrazoxane showed no clear difference in overall survival (Illustrative comparative risks reported as number… compared with no cardioprotective intervention or placebo (moderate certainty).

1 finding from 1 review

Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes only
HR 1.04 [0.88, 1.23]
4 studies · 4 participants
Moderate

Dexrazoxane vs no cardioprotective intervention or placebo

Progression‐free survival · adults with cancer receiving anthracyclines

Dexrazoxane may leads to lower progression‐free survival Defined as time from first date of… compared with no cardioprotective intervention or placebo (low certainty).

3 findings from 1 review

Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes only
HR 0.62 [0.43, 0.9]
1 study · 164 participants
Low
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes only
HR 0.95 [0.64, 1.4]
1 study · 1 participants
Low
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes only
HR 1.18 [0.97, 1.43]
2 studies · 2 participants
Moderate

Dexrazoxane vs no cardioprotective intervention or placebo

Partial response (partial or complete response) · adults with cancer receiving anthracyclines

Dexrazoxane showed no clear difference in tumour response rate Defined as number of complete or partial… compared with no cardioprotective intervention or placebo (moderate certainty).

1 finding from 1 review

Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes only
RR 0.91 [0.79, 1.04]
6 studies · 956 participants
Moderate

Dexrazoxane vs no cardioprotective intervention or placebo

Quality of life · adults with cancer receiving anthracyclines

The review found no eligible studies for this question.

1 finding from 1 review

Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found